Exelixis, Inc. (EXEL) Up 5.0% — Should I Acquire Shares Here?
Exelixis, Inc. (EXEL) delivered a decisive move in today's session, climbing 5.04% and adding $2.52 to close at $52.55 on the NASDAQ. The advance pushed shares above the prior 52-week high of $51.63 set on May 14, 2026—a meaningful technical development that places EXEL at fresh territory and resets the benchmark for what bulls can now defend. Breaking through a 52-week high is rarely a coincidence, and in this case it came on the back of a clear, company-specific catalyst that gave the market a concrete reason to reprice the stock higher.
Trading volume came in at approximately 1.02 million shares, running well below the 90-day average of roughly 2.74 million. The lighter-than-usual turnover accompanying an all-time-high close is a notable observation—price discovery pushed higher without requiring outsized participation, suggesting the move was driven by conviction rather than a frenzied crowd. As awareness of the catalyst spreads, the potential for volume to catch up to price action adds another layer of interest for momentum-oriented investors.
Why Exelixis, Inc. Price is Moving Higher
The immediate catalyst behind EXEL's surge is the announcement of a new clinical development collaboration with Merck, which will evaluate one of Exelixis's pipeline candidates in a joint trial setting. Partnerships with Merck carry significant signaling value in oncology—they do not materialize without rigorous scientific diligence on both sides—and for Exelixis, the deal reframes how the market should think about pipeline optionality beyond the company's established cabozantinib franchise. Investors responded by revaluing the stock upward, and the breach of the prior 52-week high confirms that the repricing has conviction behind it.
The fundamental backdrop makes that repricing easier to sustain. Exelixis is not a speculative pipeline story asking investors to take a leap of faith—it is a profitable, cash-generating biotech with a trailing P/E of roughly 16.57 and a market cap of approximately $12.58 billion. Revenue growth of 9.97% and a profit margin of 35.08% demonstrate that the core cabozantinib business continues to expand while throwing off substantial earnings. When a company with that kind of earnings power announces a meaningful collaboration with one of the world's leading drug developers, the market has a clear framework for assigning additional value to what was previously discounted as speculative upside.
The broader setup amplifies the move's significance. EXEL's forward P/E of 16.59 is strikingly modest for a Health Care name with a 35% profit margin and a freshly expanded pipeline partnership. That combination—visible earnings power, reasonable valuation, and a new high-profile collaboration—gives investors arriving at this price level a well-defined fundamental anchor rather than a stretched entry. Recent insider selling has been noted in the market commentary, but price action and volume tell a more current story: buyers stepped in decisively on news of genuine strategic progress, and the stock has now set a new high-water mark as a result.
What is the Exelixis, Inc. Rating - Should I Buy?
Weiss Ratings assigns EXEL a B rating. Current recommendation is Buy. The overall rating reflects a company that is firing on virtually every fundamental dimension, with the sub-index profile offering one of the cleaner reads in the Health Care sector for investors seeking quality alongside growth.
ROE of 40.99% earns the Excellent Efficiency Index—a standout figure for a pharmaceutical company that funds its own pipeline development without relying heavily on dilutive equity raises or leveraged balance sheet tactics. That capital efficiency, paired with revenue growth of 9.97% and a profit margin of 35.08%, underpins the Excellent Growth Index and Excellent Solvency Index as well. Together these three metrics describe a business that is growing its top line, converting a substantial portion of it into earnings, and doing so from a position of financial strength rather than financial strain—a combination that is genuinely uncommon among mid-cap biotechs navigating competitive drug markets.
The Fair Total Return Index is the one area that tempers an otherwise uniformly positive sub-index picture. It reflects the reality that EXEL's total return record over the measurement period has not yet separated itself from the pack, a dynamic that the current breakout above the 52-week high may begin to address if momentum continues. The Good Volatility Index provides additional reassurance that while the stock can move meaningfully on catalysts—as Thursday's session demonstrated—it does not carry the extreme swing risk that tends to accompany earlier-stage biotech names. That combination of manageable volatility and strengthening momentum is precisely the profile many risk-adjusted investors actively seek.
Within the Health Care sector, Exelixis is on equal footing with Johnson & Johnson (JNJ, B), Amgen Inc. (AMGN, B), and Gilead Sciences, Inc. (GILD, B), while ranking ahead of Eli Lilly and Company (LLY, B-) and Vertex Pharmaceuticals Incorporated (VRTX, B-). That positioning is notable given EXEL's significantly smaller market cap—it is holding its own against large-cap pharma franchises on a fundamentals-driven ratings basis, which speaks to the quality of the underlying business model.
About Exelixis, Inc.
Exelixis, Inc. (EXEL) is a Health Care company operating within the Pharmaceuticals, Biotechnology and Life Sciences industry, with a commercial and research focus anchored in oncology. The company built its commercial foundation on cabozantinib, a small-molecule inhibitor that targets multiple receptor tyrosine kinases and has earned regulatory approvals across several tumor types, including renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Cabozantinib is marketed under the brand names CABOMETYX and COMETRIQ, and it generates the revenue base that funds Exelixis's ongoing clinical and early-stage pipeline work—an unusual arrangement in biotech where a single approved asset sustains a self-funded development engine.
That self-funding capacity is central to understanding Exelixis's competitive position. The company does not need to access capital markets to keep its pipeline advancing, which means it retains more control over development timelines, partnering decisions, and capital allocation than peers that are still pre-revenue or operating at a loss. Its pipeline includes multiple investigational compounds at various stages of clinical evaluation, spanning targeted therapies and antibody-drug conjugates designed to address cancers where current treatment options remain limited. The collaboration with Merck announced this week adds a high-profile external validation layer to one of those pipeline candidates, providing both trial resources and the credibility that comes with a major industry partner's scientific endorsement.
Exelixis maintains a meaningful intellectual property portfolio around cabozantinib and its development compounds, with patent protection and regulatory exclusivity supporting the durability of its revenue stream. The company's ability to generate a 35% profit margin while simultaneously funding discovery-stage research reflects operational discipline that is difficult to replicate for competitors without an equivalent commercial anchor. That rare combination of a proven revenue-generating drug, a self-funded pipeline, and now an expanded collaboration network positions Exelixis as a differentiated player within a sector that rewards companies capable of sustaining both current earnings and future optionality.
Investor Outlook
Exelixis, Inc. (EXEL) carries a Weiss Rating of B (Buy), and Thursday's push above the prior 52-week high marks a constructive inflection point that performance-oriented investors will be watching closely. In the near term, the key variables are whether EXEL can consolidate above the former resistance level now turned support, and how the market continues to digest the scope and terms of the Merck collaboration as additional details emerge. Any updates on trial design, enrollment timelines, or further pipeline news could serve as the next meaningful catalyst for shares. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--